Home > Insider Trading > Filing (0001415889-25-002819)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1674632	Beta Bionics Inc.	BBNX	Surgical & Medical Instruments & Apparatus (3841)	475386878

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
2048500	Mike Mensinger	C/O Beta Bionics 11 Hughes Irvine CA 92618	Chief Product Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2025-01-31	15,107	$0.00	15,107	No	4	C	Direct
Common Stock	Acquisiton	2025-01-31	10,575	$0.02	25,682	No	4	X	Direct
Common Stock	Disposition	2025-01-31	13	$17.00	25,669	No	4	S	Direct
Common Stock	Acquisiton	2025-01-31	33,350	$17.00	59,019	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	X	Direct
No	4	S	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series D Preferred Stock	Disposition	2025-01-31	15,107	$0.00	15,107	$0.00
Common Stock	Class B Common Stock Warrant (right to buy)	Acquisiton	2025-01-31	10,575	$0.00	10,575	$0.02
Common Stock	Class B Common Stock Warrant (right to buy)	Disposition	2025-01-31	10,575	$0.00	10,575	$0.02
Common Stock	Employee Stock Option (right to buy)	Acquisiton	2025-01-31	236,553	$0.00	236,553	$5.10
Common Stock	Employee Stock Option (right to buy)	Acquisiton	2025-01-31	110,278	$0.00	110,278	$17.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
10,575	2023-08-28	2033-08-27	No	4	C	Direct
0	2023-08-28	2033-08-27	No	4	X	Direct
236,553		2033-09-13	No	4	A	Direct
110,278		2025-01-28	No	4	A	Direct

Footnotes

Immediately prior to the closing of the initial public offering, each share of Series D Preferred Stock (the "Preferred Stock") was converted into an equal number of shares of Class B Common Stock and subsequently was converted into an equal number of shares of Common Stock without payment of further consideration. The Preferred Stock had no expiration date.
On January 31, 2025, the reporting person exercised a warrant to purchase 10,575 shares of Issuer's common stock for $0.02 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in withholding of 13 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 10,562 shares.
The shares were purchased in the Issuer's initial public offering.
Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this warrant was converted into an equal number of shares of Common Stock.
One-fourth of the shares subject to this option shall vest one year after August 1, 2023, and thereafter 1/36th of the shares subject to this option shall vest on each monthly anniversary thereof.
Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock.
Vesting is monthly over a 48-month period starting January 29, 2025 in equal monthly amounts.